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approximately two times higher for Japanese men with noc-
turia (357 men aged 70 years and over, 5-year follow-up). 
A univariable association between nocturia and all-cause 
mortality was found in Dutch men, but not in age-adjusted 
analyses (1114 men aged 50–78 years, 13-year follow-up).
Conclusion This meta-analysis conducted on longitudinal 
studies does not confirm LUTS to be a predictor of CVD in 
men without a history of CVD, despite the observed asso-
ciation between LUTS and CVD in cross-sectional studies.
Keywords Ageing male · Cardiovascular diseases · 
Lower urinary tract symptoms · Systematic review/ 
meta-analysis
Introduction
Cardiovascular diseases (CVD) are the leading cause of 
death globally and cause high morbidity [1]. The increasing 
prevalence of CVD in the ageing population necessitates 
the timely identification of people who are at risk [2]. It has 
been suggested that lower urinary tract symptoms (LUTS) 
are associated with CVD and may predict cardiovascular 
events. These conditions share multiple risk factors such as 
obesity, diabetes, hypertension, smoking, and advanced age 
[3–7]. If so, therapeutic interventions to improve LUTS at 
an early stage may be considered to prevent morbidity and 
mortality due to CVD. Also screening of men with LUTS 
on cardiovascular diseases will be meaningful.
The pathogenesis of LUTS is considered to be multi-
factorial, in which age-related changes in prostate, bladder 
structure, and bladder function seem to play a central role. 
Vascular diseases such as atherosclerosis and endothelial 
dysfunction in the pelvic vascular system might contribute 
to bladder dysfunction with age [3]. The risk factors for 
Abstract 
Purpose To study the incidence of CVD in men at risk, 
with and without LUTS.
Methods We searched all longitudinal studies describ-
ing the association between LUTS and CVD (mortality) 
in October 2013 and December 2014 using MEDLINE, 
EMBASE, and the Cochrane Library Central Register. 
PRISMA criteria were met.
Results We included five studies with 6027 men with 
LUTS and 18,993 men without LUTS in the meta-anal-
yses, with a follow-up period varying from 5 to 17 years. 
Studies totalled 2780 CVD events. No clear association 
between CVD and LUTS was demonstrated [pooled effect 
size: hazard ratio 1.09 (95 % CI 0.90–1.31); p = 0.40]. 
Two other studies reported the association between noc-
turia and (CVD) mortality. CVD-specific mortality risk was 
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vascular diseases and atherosclerosis might also have an 
impact on LUTS via other mechanisms [8]. For instance, 
increased sympathetic activity and/or a1-adrenoreceptor 
activity is suggested as the common pathway for both 
hypertension and LUTS [9]. Nicotine, but also waking by 
nocturia [10, 11], increases the sympathetic nervous system 
activity and may contribute to LUTS via an increase in the 
tone of the prostate [12, 13]. Hypertension and heart failure 
can cause fluid shifts and hormonal and autonomic nervous 
disturbances, causing LUTS. Finally, neurogenic bladder 
dysfunction with detrusor underactivity can cause LUTS in 
patients with diabetes mellitus [3].
Previous studies already reported on the association 
between LUTS and CVD in cross-sectional settings, per-
formed in both clinical and community-based populations 
[3–7, 9, 14, 15]. It remained unclear whether this associa-
tion between LUTS and CVD reflects a true increased risk 
of CVD, or if it is mainly explained by, for example, age, 
which is strongly associated with both LUTS and CVD [1, 
16]. The outcomes are heterogeneous [3–7]. More recently, 
longitudinal studies have been published.
To better understand the possible relationship between 
LUTS and CVD and to know whether LUTS is a precur-
sor for CVD in people without a history of CVD, we per-
formed a systematic review and meta-analysis based on 
longitudinal studies. We were especially interested in deter-




We conducted a systematic review of the literature. Poten-
tially relevant studies were identified through a structured lit-
erature search of MEDLINE, EMBASE, Cochrane Database 
of Systematic Reviews, and Cochrane Central Register of 
Controlled Trials using Medical Subject Headings (MeSH) 
and free-text keywords. The terms LUTS AND CVD AND 
(cohort studies OR longitudinal studies) were combined, 
using various synonyms presented in “Appendix 1”.
We identified articles eligible for further review by per-
forming an initial screen of identified titles and abstracts, 
followed by a full-text review. In addition, we searched the 
reference list of all identified relevant publications on Octo-
ber 20, 2013, and repeated the complete search on Decem-
ber 10, 2014.
Inclusion, exclusion, and quality score criteria
Two investigators (IB and MV) independently assessed lit-
erature eligibility. Articles were considered for inclusion 
if: (1) the study included original data, published in a 
peer-reviewed journal (i.e. not review articles, or meeting 
abstracts); (2) the study was a cohort study (prospec-
tive cohort or historical cohort) consisting of male human 
adults; and (3) the authors reported the risk estimates of 
cardiovascular morbidity in LUTS patients compared with 
non-LUTS patients. Selected studies included all types of 
CVD, cardiovascular risk, and LUTS.
To assess the methodological quality of included stud-
ies, a structured form was used. We chose to apply a score 
based on a criterion list which has been previously used in 
systematic reviews of observational data [17, 18]. We tai-
lored the list by adding criteria on the completeness of data 
on LUTS and CVD. The list included six items on external 
validity, five items on internal validity, and seven items on 
informativity (“Appendix 2”). IB and MV independently 
scored all items either positive (scored as 1) or negative 
(scored as 0).
Data extraction
Two reviewers (IB and MV) independently extracted the 
following information about the studies: study characteris-
tics (study name, authors, publication year, journal, study 
site, follow-up years, and number of participants), partici-
pants’ characteristics (mean age or age range), main expo-
sure LUTS (IPSS, AUA, and nocturia), main outcome car-
diovascular disease/risk (morbidity, risk, types, assessed 
by self-report, and medical records), and analysis strategy 
(statistical models, covariates included in the models). Dis-
agreement about data extraction or the quality score of the 
included studies was resolved by consensus. When no or 
insufficient information was provided in the article, earlier 
publications on the same study were used for collecting 
lacking information, if available. For pooling of data, on 
our request, we received additional information from two 
studies (personal communication—Wehrberger et al. [19] 
and Lin [20]). This concerned information about hazard 
ratios for CVD risk in men with moderate to severe LUTS, 
compared to men with no or mild LUTS.
Meta‑analyses
We selected studies that compared the incidence of a 
CVD between individuals with and without LUTS. Stud-
ies including patients with only (cardiovascular) mortality 
as an endpoint were considered not fully representative of 
CVD. Therefore, we did not include these studies in the 
meta-analysis but analysed these studies separately.
In all analyses, we considered methodological homo-
geneity. If data were pooled, statistical heterogeneity was 
assessed using the I2 index. In case of substantial hetero-
geneity (I2 ≥ 50 %), a random effects model was applied. 
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A fixed effects model was used when I2 < 50 %. Weighted 
hazard ratios (HR) were presented with 95 % confidence 




We reviewed seven studies (with 25,982 male participants) 
selected from 1082 initially identified publications (Fig. 1). 
This selection included four community-based studies [10, 
19–21] and one primary care study [22]. In two other stud-
ies (1471 participants), nocturia and (CVD) mortality were 
assessed [23, 24]. Background information for these stud-
ies is presented in Tables 1 and 2.
Methodological quality assessment and description 
of selected studies
Table 3 shows the results of the quality assessment. The 
proportions scored positive were 0.71 on external valid-
ity, 0.74 on internal validity, and 0.88 on informativity. In 
89 % of the items, there was a positive agreement, whereas 
in 11 % of the items consensus was reached after discus-
sion between the two reviewers. None of the studies scored 
positive on all validity criteria.
LUTS and CVD
The five studies included in the meta-analysis compared 
CVD outcomes between in total 6027 men with LUTS and 
18,993 men without LUTS. Two studies reported a median 
follow-up of 17.1 and 11.0 years [10, 22]; three other 
Fig. 1  Flowchart of study selection
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studies reported a mean duration of follow-up of 6.1, 6.35, 
and 6.6 years [19–21]. During this follow-up, a total of 
2780 CVD events occurred: 646 in men with LUTS (17 %), 
compared to 1775 in men without LUTS (10 %). Lightner 
et al. [10] only report a total of 359 men with CVD in the 
follow-up group.
Figure 2 shows the results of the pooled analyses with an 
estimated hazard ratio of 1.09 (95 % CI 0.90–1.31), p = 0.40.
Nocturia and (cardiovascular) mortality
Two studies described the CVD mortality risk for men 
with and without nocturia [23, 24]. Nakagawa et al. [24] 
conducted a community-based observational study and fol-
lowed 784 men aged 70 years and older, of whom 359 had 
nocturia. During a 5-year observation period, these men 
had a two times greater risk to die from CVD than the men 
without nocturia: HR 1.98, 95 % CI 1.09–3.59, p = 0.03. In 
this analysis, the authors adjusted for sex, alcohol, tobacco, 
diabetes, medication, CVD history, nephropathy, malignant 
disease, BMI, and functional reach.
Van Doorn et al. [23] conducted a similar observational 
study with 1114 men aged 50 years and older with an 
extended follow-up period of 13.4 years. At baseline, 731 
had no nocturia and 383 had nocturia. During a median 
follow-up period, there was an association between noc-
turia and increased mortality rate in the univariable analysis 
(HR 1.63, 95 % CI 1.20–2.21, p = 0.002). This association 
between nocturia and all-cause mortality was not found 
in the model adjusting for age, COPD, hypertension, and 
smoking: the adjusted HR was 1.03 (95 % CI 0.75–1.42).
Discussion
This systematic review and meta-analysis of longitudinal 
studies does not confirm that LUTS is a precursor for CVD, 
as has been suggested from cross-sectional studies [3–7, 9, 
14, 15]. This might implicate that the presence of LUTS 
in older men is no reason to start preventive cardiovascu-
lar treatment. At least, raising public awareness on CVD in 
men with LUTS seems not to have a scientific ground.
The number of available studies on this topic was limited; 
only seven cohort studies with 25,982 participants between 
LUTS and CVD, or nocturia and (cardiovascular) mortal-
ity were available for review. In general, longitudinal stud-
ies are more laborious and expensive to perform, but vital to 
analyse possible causal relationships. Earlier cross-sectional 
studies showed apparently clear association between LUTS 
and cardiovascular risk factors [3, 4, 6, 7, 9, 14, 15]. No 
inference can be made on the causality of such associations.
The results of longitudinal studies should also be consid-
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methods need to be sound. The preferred statistical method is 
survival analyses. In such analyses, time to event is the out-
come. This is especially important for severe outcomes, such 
as CVD. In a very recent longitudinal study on this topic [7], 
authors concluded that LUTS severity predicts CVD. In that 
study, however, authors applied logistic regression analyses, 
instead of survival analyses. We believe that this statistical 
method is inferior to survival analyses and may have led to 
an overestimation of the studied association. Comparing pro-
portions of events in study groups using odds ratios/logistic 
regression ignores time as an important factor [25]. Moreo-
ver, due to this difference, that study could not be included in 
the current meta-analysis.
Longitudinal studies may provide a temporal sequence 
of events required for revealing time-dependent relation-
ships between LUTS and CVD or mortality. In this respect, 
we focussed on this temporal sequence and not on the 
reverse sequence of the possible negative impact of CVD 
(treatment) on the development of LUTS.
The absence of a clear association described in this 
review needs to be interpreted with some caution. The stud-
ies included in this review were based on general population 
samples, health registries, and one general practice popula-
tion. In such populations, men with severe LUTS, as well as 
high-risk patients, may be underrepresented. For example, 
in the Wehrberger study, only 1 % of the participants had 
severe LUTS. This small group had a higher risk of CVD 
than men without LUTS [19]. Adding this group to the men 
with moderate LUTS, for the purpose of pooling the data in 
the current meta-analysis, revealed no significant difference 
compared to men without LUTS. Longitudinal studies in 
high-risk patients are lacking. Surprisingly, no data from sec-
ondary or tertiary care settings were found.
Second annotation is made on the applied definitions of 
both LUTS and CVD, which differed between studies. As 
defined by the European Association of Urology (EAU), 
LUTS is a very broad concept which incorporates a range 
of micturition symptoms [26]. Likewise, CVD includes 
a broad number of diseases, not always sharing the same 
aetiology. Included studies did not always specify for myo-
cardial infarction, peripheral vascular disease, or stroke. 
Being unable to find an association in our review could also 
be due to these different aetiologies between and within 
LUTS and CVD. On the other hand, from a methodological 
point of view, applying different definitions could enhance 
making firm conclusions, if a clear association would have 
been shown in all studies. In the current review, in only one 
out of five studies, a significant association was found [20].
Finally, as both LUTS and CVD are believed to have a mul-
tifactorial origin [1, 16], other possible causes of CVD, such 
as nicotine abuse, hyperlipidaemia, BMI, and alcohol abuse, 
should also be considered in studying the association between 
LUTS and clinical CVD. Although all studies reported imple-
menting adjustments for confounding factors such as age, 
gender, and smoking status, not all known cardiovascular risk 
factors were included in the longitudinal analyses. This might 
have had impact on the described associations.
So, although our review suggests that LUTS do not pre-
dict CVD in men without a history of CVD, the association 
between LUTS and CVD could not be ruled out.
Next to these general concerns on the available data, some 
methodological issues need to be mentioned as well. We 
have searched relevant databases, but with our search strat-
egy, individual studies might have been overlooked. For that 
reason, we also checked the reference lists. We have applied 
a criteria list for the methodological quality assessment, pre-
viously used in comparable reviews [17, 18]. This included 
some arbitrary items, for example, on the availability of fol-
low-up percentages and information on losses to follow-up. 
It is impossible to provide such data, for example, from reg-
istry studies, resulting in a lower quality score for such stud-
ies. Next, for the meta-analyses, we have chosen to perform 
pooled analyses, despite the clinical heterogeneity present. 
Evaluating the separate studies, however, would have led to 
the same conclusions, as four of the five studies showed no 
association. Due to the statistical heterogeneity, we needed to 
Fig. 2  Risk (hazard ratio) of CVD according to LUTS status. Pooled hazard ratio with 95 % CI resulting from meta-analyses using generic 
inverse variance random effects model. Presentation in order of publication year
1918 World J Urol (2015) 33:1911–1920
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adjust the analyses, by performing a random effects model. 
We could not perform subgroup analyses.
Conclusion
Despite the limitations addressed, we conclude that the pres-
ence of LUTS does not predict CVD in older men without 
a history of CVD. Raising awareness for CVD in men with 
LUTS in the general population seems to have no evidence 
base. No information was found on this association in more 
selective clinical samples. To further address LUTS as a pos-
sible marker of underlying CVD, high-quality prospective 
research in a clinical setting is needed. This should be done 
applying generally accepted definitions of LUTS and CVD.
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CVD (“Cardiovascular Diseases” [Mesh:NoExp]) OR 
(“Heart Diseases” [Mesh:NoExp]) OR (“Arrhyth-
mias, Cardiac” [Mesh]) OR (“Heart Arrest” [Mesh]) 
OR (“Heart Failure” [Mesh]) OR (“Myocardial 
Ischemia” [Mesh]) OR (“Pulmonary Heart Disease” 
[Mesh]) OR (“Vascular Diseases” [Mesh:NoExp]) 
OR (“Arteriosclerosis” [Mesh]) OR (“Carotid 
Stenosis” [Mesh]) OR (“Cerebrovascular Disor-
ders” [Mesh]) OR (“Embolism and Thrombosis” 
[Mesh]) OR (“Hypertension” [Mesh]) OR (“Myo-
cardial Ischemia” [Mesh])OR “cardiovascular 
disease” OR “coronary heart disease” OR “ischemic 
heart disease” OR “coronary artery disease” OR 
“hypertensive heart disease” OR “cor pulmonale” 
OR “cerebrovascular disease” OR “peripheral 
arterial disease” OR “stroke” OR “atherosclerosis” 
OR “myocardial ischemia” OR “acute coronary 
syndrome” OR “angina pectoris” OR “coronary dis-
ease” OR “coronary artery disease” OR “coronary 
occlusion” OR “coronary stenosis” OR “coronary 
thrombosis” OR “myocardial infarction” OR “sud-
den death”
Keyword Synonym
LUTS (“prostatic Hyperplasia” [Mesh]) OR (“Lower 
Urinary Tract Symptoms” [Mesh]) OR (“Urina-
tion Disorders” [Mesh]) OR (”Urinary bladder 
neck obstruction” [MeSH])OR (“Urinary Bladder, 
overactive” [Mesh])OR (“Polyuria” [Mesh]) OR 
“dysuria” OR “nocturia” OR “prostatism” OR 
“overactive urinary bladder” OR “overactive blad-
der” OR “urinary incontinence” OR “urgency” OR 
“Hesitancy” OR “lower urinary tract symptoms” 
OR “benign prostatic hyperplasia” OR “benign 
prostatic hypertrophy” OR “prostatic hyperplasia” 
OR “prostatic hypertrophy” OR “bladder outlet 
obstruction” OR “voiding dysfunction” OR “urinary 
bladder neck obstruction” OR “prostatic Hyperpla-
sia” [Mesh] OR “Lower Urinary Tract Symptoms” 
[Mesh] OR “Urination Disorders” [Mesh] OR 
“Urinary bladder neck obstruction” [MeSH] “Uri-
nary Bladder, overactive” [Mesh] “Polyuria” [Mesh] 
OR “dysuria” OR “nocturia” OR “prostatism” OR 
“overactive urinary bladder” OR “overactive blad-
der” OR “urinary incontinence” OR “urgency” OR 
“Hesitancy” OR “lower urinary tract symptoms” OR 
“benign prostatic hyperplasia” OR “benign prostatic 
hypertrophy” OR “prostatic hyperplasia” OR “pro-
static hypertrophy” OR “bladder outlet obstruction” 




“Longitudinal Studies” [Mesh] OR “Longitudinal 
Studies”
Cohort studies “Cohort Studies” [Mesh] OR “Cohort Studies”
Appendix 2
Quality score criteria and informativitya
External validity
Selection of the study population
 A Clear description of the research 
population?b
 B Inclusion and exclusion criteria 
described?c
Participants and non-responders
 C Response rate >70 % or sufficient 
information on non-responders?d
 D Is there sufficient information 
about the follow-up percentages 
and comparison of who were and 
were not lost to follow-up?
Relationship with source population?
 E Extrapolating results possible for 
the complete population?e
Description of the study period
 F Clear description of the study 
period?




 G Data prospectively collected?
Measurement instrument
 H Measuring instrument for LUTSf
 I Measuring instrument for CVDg
 J Are definitions of the diseases 
stated?
Confounders
 K Confounders described?h
Informativityi
L Clear theoretical introduction with 
relevant references to support the 
research question?
M Aims of the study clearly 
described?
N Research questions being 
answered?
O Definition of LUTS clearly 
described
P Definition of CVD clearly 
described
Q Clear description of the way data 
were analysed?
R Enough original data to evaluate 
their interpretation
a Items were scored positive if clear information was presented in the 
articles. Unclear data are presented as “?” and consequently scored 
negative for the quality score summation
b Clear description of source and two or more of the following: age 
distribution, relevant comorbidity, medication
c Scored positive if both inclusion and exclusion criteria were pro-
vided
d Sufficient information on non-responders: were reasons for non-
response studied and presented, including information on age distribu-
tion, gender, main topic under study?
e Did the study selection procedure result in a representative sample 
of the study population?
f Data on LUTS collected through IPSS or validated questionnaire
g Data on CVD collected through validated instrument
h Description of confounders not necessarily including actual statisti-
cal adjustment for confounders
i Informativity was not included in the quality score
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creativecom-
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution, 
and reproduction in any medium, provided you give appropriate credit 
to the original author(s) and the source, provide a link to the Creative 
Commons license, and indicate if changes were made.
References
 1. Laslett LJ, Alagona P, Clark BA et al (2012) The worldwide 
environment of cardiovascular disease: prevalence, diagnosis, 
therapy, and policy issues: a report from the American College 
of Cardiology. J Am Coll Cardiol 60:S1–S49. doi:10.1016/j.
jacc.2012.11.002
 2. Yach D, Hawkes C, Gould CL, Hofman KJ (2004) The global 
burden of chronic diseases: overcoming impediments to pre-
vention and control. JAMA 291:2616–2622. doi:10.1001/
jama.291.21.2616
 3. Ponholzer A, Temml C, Wehrberger C et al (2006) The asso-
ciation between vascular risk factors and lower urinary tract 
symptoms in both sexes. Eur Urol 50:581–586. doi:10.1016/j.
eururo.2006.01.031
 4. Sandfeldt L, Hahn RG (2003) Cardiovascular risk factors cor-
relate with prostate size in men with bladder outlet obstruction. 
BJU Int 50:64–68. doi:10.1046/j.1464-410X.2003.04277.x
 5. Karatas OF, Bayrak O, Cimentepe EUD (2010) An insidious risk 
factor for cardiovascular disease: benign prostatic hyperplasia. 
Int J Cardiol 144:452
 6. Ng CF, Wong A, Li ML et al (2007) The prevalence of cardiovas-
cular risk factors in male patients who have lower urinary tract 
symptoms. Hong Kong Med J 13:421–442
 7. Kupelian V, Araujo AB, Wittert GA, McKinlay B (2014) Asso-
ciation of moderate to severe lower urinary tract symptoms with 
incident type 2 diabetes and heart disease. J Urol. doi:10.1016/j.
juro.2014.08.097
 8. Shimizu S, Tsounapi P, Shimizu T et al (2014) Lower urinary 
tract symptoms, benign prostatic hyperplasia/benign pros-
tatic enlargement and erectile dysfunction: are these condi-
tions related to vascular dysfunction? Int J Urol 21:856–864. 
doi:10.1111/iju.12501
 9. Kim S, Jeong JY, Choi YJ et al (2010) Association between 
lower urinary tract symptoms and vascular risk factors in aging 
men: the Hallym Aging Study. Korean J Urol 51:477–482
 10. Lightner DJ, Krambeck AE, Jacobson DJ et al (2012) Nocturia is 
associated with an increased risk of coronary heart disease and death. 
BJU Int 110:848–853. doi:10.1111/j.1464-410X.2011.10806.x
 11. Kupelian V, Fitzgerald MP, Kaplan SA et al (2011) Associa-
tion of nocturia and mortality: results from the Third National 
Health and Nutrition Examination Survey. J Urol 185:571–577. 
doi:10.1016/j.juro.2010.09.108
 12. Rohrmann S, Smit E, Giovannucci E, Platz EA (2005) Associa-
tion between markers of the metabolic syndrome and lower uri-
nary tract symptoms in the Third National Health and Nutrition 
Examination Survey (NHANES III). Int J Obes (Lond) 29:310–
316. doi:10.1038/sj.ijo.0802881
 13. Michel MC, Heemann U, Schumacher H et al (2004) Association 
of hypertension with symptoms of benign prostatic hyperplasia. 
J Urol 172:1390–1393. doi:10.1097/01.ju.0000139995.85780.d8
 14. Gibbons EP, Colen J, Nelson JB, Benoit RM (2007) Correla-
tion between risk factors for vascular disease and the American 
Urological Association Symptom Score. BJU Int 99:97–100. 
doi:10.1111/j.1464-410X.2007.06548.x
 15. Kupelian V, Rosen RC, Link CL et al (2009) Association of 
urological symptoms and chronic illness in men and women: 
contributions of symptom severity and duration—results 
from the BACH Survey. J Urol 181:694–700. doi:10.1016/j.
juro.2008.10.039
 16. Chapple CR, Wein AJ, Abrams P et al (2008) Lower urinary tract 
symptoms revisited: a broader clinical perspective. Eur Urol 
54:563–569. doi:10.1016/j.eururo.2008.03.109
 17. Prins J, Blanker MH, Bohnen AM et al (2002) Review Preva-
lence of erectile dysfunction: a systematic review of popula-
tion-based studies. Int J Impot Res 14:422–432. doi:10.1038/
sj.ijir.3900905
 18. Hofmeester I, Kollen BJ, Steffens MG et al (2014) The associa-
tion between nocturia and nocturnal polyuria in clinical and epi-
demiological studies: a systematic review and meta-analyses. J 
Urol 191:1028–1033. doi:10.1016/j.juro.2013.10.100
 19. Wehrberger C, Temml C, Gutjahr G et al (2011) Is there an asso-
ciation between lower urinary tract symptoms and cardiovascular 
1920 World J Urol (2015) 33:1911–1920
1 3
risk in men? A cross sectional and longitudinal analysis. Urology 
78:1063–1067. doi:10.1016/j.urology.2011.05.065
 20. Lin H-J, Weng S-F, Yang C-M, Wu M-P (2013) Risk of hospitali-
zation for acute cardiovascular events among subjects with lower 
urinary tract symptoms: a nationwide population-based study. 
PLoS ONE 8:e66661. doi:10.1371/journal.pone.0066661
 21. Bouwman II, Blanker MH, Schouten BWV et al (2014) Are 
lower urinary tract symptoms associated with cardiovascular dis-
ease in the Dutch general population? Results from the Krimpen 
study. World J Urol. doi:10.1007/s00345-014-1398-y
 22. Bouwman II, Kollen BJ, van der Meer K et al (2014) Are lower 
urinary tract symptoms in men associated with cardiovascular 
diseases in a primary care population: a registry study. BMC 
Fam Pract 15:9. doi:10.1186/1471-2296-15-9
 23. Van Doorn B, Kok ET, Blanker MH et al (2012) Mortality in 
older men with nocturia. A 15-year followup of the Krimpen 
study. J Urol 187:1727–1731. doi:10.1016/j.juro.2011.12.078
 24. Nakagawa H, Niu K, Hozawa A et al (2010) Impact of nocturia 
on bone fracture and mortality in older individuals: a Japanese 
longitudinal cohort study. J Urol 184:1413–1418
 25. Allison P (SAS institute inc. (2010) Survival analysis using SAS. 
336
 26. Oelke M, Bachmann A, Descazeaud A et al (2013) EAU guide-
lines on the treatment and follow-up of non-neurogenic male 
lower urinary tract symptoms including benign prostatic obstruc-
tion. Eur Urol 64:118–140. doi:10.1016/j.eururo.2013.03.004
